Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced that the U.S. Food and Drug Administration ...
Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at ...
684 free doughnuts. Our family barely purchased donuts in years.
Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public ...
Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...
Research and development expenses were $19.2 million for the three months ended September 30, 2025 compared to $18.0 million for the three months ended September 30, 2024. This increase was primarily ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing ...
The growth of the Head and Neck Cancer Drugs/Therapeutics Market is primarily driven by rising global incidence rates, increasing adoption of advanced immunotherapies, and continuous innovation ...
Depending on what type of college students attend, they may be subject to a 20-to-1 faculty ratio, like Central Michigan ...
Atea defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements in its Quarterly Report on Form 10-Q for the three months ended ...
In the intricate architecture of plant tissues, beauty often emerges from chaos, according to new research from Cornell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback